Universität zu Köln

Kresken, Michael, Koerber-Irrgang, Barbara, Korte-Berwanger, Miriam, Pfennigwerth, Niels, Gatermann, Soeren G. and Seifert, Harald (2020). Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int. J. Antimicrob. Agents, 55 (6). AMSTERDAM: ELSEVIER. ISSN 1872-7913

Full text not available from this repository.

Abstract

Pseudomonas aeruginosa (PA) is a major cause of healthcare-associated infections. Antipseudomonal carbapenems are among the antimicrobial agents used to treat PA infections, but several mechanisms of resistance, including the production of a carbapenemase (CP), may compromise their clinical efficacy. The objectives of this study were to determine: (i) the dissemination of carbapenem-resistant CP-negative and CP-positive PA isolates; and (ii) the in-vitro activity of ceftolozane-tazobactam (CTT) against carbapenemsusceptible and carbapenem-resistant isolates. Isolates were collected prospectively from January 2016 to April 2017 at 20 German medical laboratories. Each centre was asked to provide 50 consecutive isolates from hospitalized patients. Overall, 985 isolates were collected, of which 34% were obtained from intensive care patients. Seven hundred and thirty-eight (74.9%) isolates were susceptible to both imipenem and meropenem (Subgroup I), and 247 (25.1%) isolates were resistant to carbapenems (Subgroup II): 125 (12.7%) were imipenem-resistant but meropenem-susceptible, 12 (1.2%) were meropenem-resistant but imipenem-susceptible, and 110 (11.2%) were resistant to both carbapenems (Subgroup III). A CP was detected in 28 (2.8%) isolates (predominantly VIM-2). Nine hundred and fifty (96.4%) isolates were CTTsusceptible. Susceptibility to CTT was seen in 99.6% of Subgroup I isolates, 87% of Subgroup II isolates and 74.5% of Subgroup III isolates. Overall, 2.8% of PA produced a CP, while 22.2% were carbapenemresistant, CP-non-producing isolates. Based on these findings, CTT may be considered for treatment of PA infections, particularly those caused by multi-drug-resistant CP-non-producing isolates. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kresken, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Koerber-Irrgang, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Korte-Berwanger, Miriam UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfennigwerth, Niels UNSPECIFIED UNSPECIFIED UNSPECIFIED Gatermann, Soeren G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Seifert, Harald UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-331373
DOI:	10.1016/j.ijantimicag.2020.105959
Journal or Publication Title:	Int. J. Antimicrob. Agents
Volume:	55
Number:	6
Date:	2020
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	1872-7913
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language METALLO-BETA-LACTAMASES; IN-VITRO; ENTEROBACTERIACEAE; FR264205; GENE Multiple languages Infectious Diseases; Microbiology; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/33137